

Resonance Health Ltd
ASX Release

27 May 2015

HepaFat-Scan® technology in US study addressing fatty liver disease in children

The Board of Resonance Health is pleased to announce that agreement has been reached with Emory University, who will perform a validation study of the Company's HepaFat-Scan® technology in a paediatric patient population with Non-Alcoholic Fatty Liver Disease (NAFLD) at a prestigious children's hospital in the USA – Children's Healthcare of Atlanta.


NAFLD is an obesity-related liver disease that increases the risk of liver cancer and cirrhosis, type II diabetes, cardiovascular disease and metabolic syndrome. It is the leading cause of liver disease for both adults and children in the US and is increasing rapidly worldwide. There are currently no approved pharmaceutical treatments for NAFLD.

HepaFat-Scan is a non-invasive medical imaging solution made available by Resonance Health that utilizes MRI to accurately measure liver fat. Regulatory clearances have been obtained to market HepaFat-Scan worldwide, with clearances gained in the USA (FDA), EU (CE Mark) and Australia (TGA). The gold standard for assessment of liver fat is currently liver biopsy which is painful, invasive and lacking in sensitivity due to its subjective and semi-quantitative nature.

This independent validation study of HepaFat-Scan is therefore important in consolidating the value of this test in providing an accurate liver fat measurement in NAFLD patients of all ages. General Manager of Resonance Health, Mr Sander Bangma said "We have worked with Children's Healthcare of Atlanta for a number of years in the provision of our FerriScan® service to measure liver iron overload. We are delighted that we can now further our collaboration with such a highly-respected institution to provide the HepaFat-Scan service in this study under the direction of a leading clinician in the field of paediatric NAFLD. HepaFat-Scan can assist clinicians in their diagnosis and treatment of patients, providing them with accurate information at an earlier disease stage. This study intends to show that this information will lead to improved patient outcomes. Collecting data like this may ultimately support inclusion of HepaFat-Scan in clinical guidelines for routine care of NAFLD patients."

The study will commence immediately and aims to recruit 50 subjects. Results are expected within 12 to 18 months.

HepaFat-Scan is also very well suited to be utilized by pharmaceutical companies who are currently racing to develop treatments for NAFLD and associated diseases.



For further information contact:

Sander Bangma

Resonance Health

SanderB@resonancehealth.com

P: +61 (0)8 9286 5300

W: www.resonancehealth.com

Resonance Health

Adrian Bowers

Company Secretary

T: +61 8 9286 5300

E: adrianb@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of MR medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration. HepaFat-Scan is FDA cleared for the measurement of liver fat and research continues into the development of new technology for the accurate assessment of liver fibrosis.

Facts on Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is a build-up of excess fat in the liver cells, which has the potential to damage the liver and lead to NASH (non-alcoholic steatohepatitis) and further develop into serious complications such as cirrhosis and liver cancer. Risk factors for NAFLD include overweight and obesity, diabetes and elevated triglyceride levels. Fatty liver disease is a major healthcare burden in developed countries and its prevalence is expected to increase with the global obesity epidemic and trends for developing countries to adopt Western lifestyles.

An estimated 20-30% of the US population has fatty liver disease. The US Centers for Disease Control predicts that by 2025 nearly 40% of American adults and 20-30% of American children will be obese.

An estimated one in five of the UK population has NAFLD. The cost to the National Health Service is estimated to be £4.2 billion; a figure that is likely to double by 2050.

The prevalence of NAFLD in urban India is 20-30% and accounts for almost 50% of the cases of liver cirrhosis. In China, the prevalence of fatty liver disease has doubled in the last 10 years.

The damage caused by fatty liver disease can often be halted or reversed if diagnosed before severe liver damage has occurred. HepaFat-Scan® enables patients to be accurately diagnosed without the need for invasive biopsy.